Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research
Open accessThe DOI matches its Crossref record; 148 of the 151 references it cites were found in a registry or an index.
Abstract
Phosphatidylinositol-3-kinase (PI3K) enzymes, producing signaling phosphoinositides at plasma and intracellular membranes, are key in intracellular signaling and vesicular trafficking pathways. PI3K is a family of eight enzymes divided into three classes with various functions in physiology and largely deregulated in cancer. Here, we will review the recent evidence obtained during the last 5 years on the roles of PI3K class I, II and III isoforms in tumor biology and on the anti-tumoral action of PI3K inhibitors in preclinical cancer models. The dependency of tumors to PI3K isoforms is dictated by both genetics and context (e.g., the microenvironment). The understanding of class II/III isoforms in cancer development and progression remains scarce. Nonetheless, the limited available data are consistent and reveal that there is an interdependency between the pathways controlled by all PI3K class members in their role to promote cancer cell proliferation, survival, growth, migration and metabolism. It is unknown whether this feature contributes to partial treatment failure with isoform-selective PI3K inhibitors. Hence, a better understanding of class II/III functions to efficiently inhibit their positive and negative interactions with class I PI3Ks is needed. This research will provide the proof-of-concept to develop combination treatment strategies targeting several PI3K isoforms simultaneously.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 3 PI3K cross-regulations and possible class I, II and III PI3Ks combination targeting in cancer. (A). PI3K class I isoform cross-regulations upon inhibition of one isoform. Thick lines = primary inhibition, dashed arrows = subsequent regulations. (B). PI3K cross-regulations among different classes are still poorly understood but based on this knowledge, new therapeutic strategies arise to overcome treatment resistance in cancer. (i) All PI3K classes directly or indirectly regulate mTORC1 activity. Class I PI3Kα, β, γ and δ phosphorylate PIP2 into PIP3 which allow the recruitment of PDK1 to the plasma membrane. PDK1 then activates AKT which subsequently enhances mTORC1 activity. The latter can inhibit PI3K in a negative feedback. Class II PI3K-C2α activates mTORC1 and favors its translocation to the plasma membrane via Raptor association to PIP2 [135,140]. On the contrary, PI3K-C2β produces PI(3,4)P2, allowing the link of 14-3-3 which represses mTORC1 [136]. Loss of PI3K-C2γ is responsible for an mTOR activation [96]. Vps34 allows the amino acid activation of the phospholipase D1 (PLD1) which then translocates to the lysosome and stimulates mTORC1 activity [141] but can also inhibit PDK1 sumoylation which results in less AKT and mTOR activation. (ii) Vps34 regulates autophagy while class I PI3Ks modulate proliferation. Both mechanisms are important for cancer cell survival. (iii) Class III PI3K Vps34 can indirectly modulate PI3Kβ activity by allowing PTEN relocalization to intracellular PI(3)P vesicles whose level is regulated by Vps34 [138]. (iv) Vps34 inhibition triggers PD-L1 expression [118] while PI3Kδ induces the expression of PD-1 in CD8+ cells [139]. “ON” means that the protein is activated while “OFF” means it is inactivated or absent. Red inhibition or activation lines correspond to possible combination therapies that could be inhibitory or activatory. Of note, all these pathways were demonstrated in different cell types and contexts; the large significance of these data is currently unknown.](https://figures.cochat.ai/paper-figures/5ec3a62f19a64e1a9c6e572662090fa9/targeting-class-i-ii-iii-pi3ks-in-cancer-therapy-recent-advances-in-tumor-figure-3.jpg)

![Figure 2 Engagement of class I PI3K isoforms in cancer depending on genetic alterations or context-dependent activation. Tumors’ specific dependency on PI3K inhibitors is mainly based on (i) genetic alterations and (ii) context-dependent activation of isoforms. (i) Oncogenic activation of PI3Kα catalytic domain leads to PI3Kα sensitivity while PI3Kβ gene amplification or PTEN loss is responsible for PI3Kβ inhibitors’ efficacy. RAS oncogenic activation directly couples with PI3Kα,γ or δ isoforms (but not PI3Kβ) [49,50]. (ii) GSK3β-dependent inhibitory phosphorylation of PTEN could possibly increase sensitivity to PI3Kα or PI3Kβ inhibitors. Inflammatory context (e.g., TNFα [17], GPCR ligand S1P [43]) activates PI3Kα or PI3Kβ/PI3Kγ, respectively. Mechanical signals possibly promote PI3Kβ activation [40]. Increased expression of PI3Kγ promotes PI3K activation [51].](https://figures.cochat.ai/paper-figures/41b41a4b38384f7caace314a0d0cff93/targeting-class-i-ii-iii-pi3ks-in-cancer-therapy-recent-advances-in-tumor-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is a major downstream signaling cascade of EGFR and represents an important bypass mechanism contributing to resistance to cetuximab and panitumumab [40,41,42,43,44].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yue, D., & Sun, X. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0960-8 · Cited by 40
RetractedThe emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767 · cited 2×
“This therapeutic strategy was supported by the fact that, even though all class I PI3Ks catalyze the same reaction, they show distinct relevance in each organ and in each tumor type [2].”
BackgroundSelf-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis
Takahashi, Y., Coppola, D., Matsushita, N., Cualing, H. D., Sun, M., Sato, Y., Liang, C., Jung, J. U., Cheng, J. Q., Mul, J. J., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1634 · Cited by 927
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
PI3K isoforms in cell signalling and vesicle trafficking
Bilanges, B., Posor, Y., & Vanhaesebroeck, B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0129-z · Cited by 525
Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
Graupera, M., Guillermet-Guibert, J., Foukas, L. C., Phng, L.-K., Cain, R. J., Salpekar, A., Pearce, W., Meek, S., Millan, J., Cutillas, P. R., et al. (2008) · Nature · doi:10.1038/nature06892 · Cited by 520
Self-citationPI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Phosphoinositides as membrane organizers
Posor, Y., Jang, W., & Haucke, V. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00490-x · Cited by 469
Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola-Villegas, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432
Furuya, N., Yu, J., Byfield, M., Pattingre, S., & Levine, B. (2005) · Autophagy · doi:10.4161/auto.1.1.1542 · Cited by 429
Adhesion to fibronectin regulates Hippo signaling via the FAK–Src–PI3K pathway
Kim, N.-G., & Gumbiner, B. M. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201501025 · Cited by 421
An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway
Shin, H.-W., Hayashi, M., Christoforidis, S., Lacas-Gervais, S., Hoepfner, S., Wenk, M. R., Modregger, J., Uttenweiler-Joseph, S., Wilm, M., Nystuen, A., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505128 · Cited by 397
Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function
Jaber, N., Dou, Z., Chen, J.-S., Catanzaro, J., Jiang, Y.-P., Ballou, L. M., Selinger, E., Ouyang, X., Lin, R. Z., Zhang, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112848109 · Cited by 385
Guillermet-Guibert, J., Bjorklof, K., Salpekar, A., Gonella, C., Ramadani, F., Bilancio, A., Meek, S., Smith, A. J. H., Okkenhaug, K., & Vanhaesebroeck, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707761105 · Cited by 345
Self-citationFan, R., Kim, N.-G., & Gumbiner, B. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216462110 · Cited by 336
RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
Fritsch, R., de Krijger, I., Fritsch, K., George, R., Reason, B., Kumar, M. S., Diefenbacher, M., Stamp, G., & Downward, J. (2013) · Cell · doi:10.1016/j.cell.2013.04.031 · Cited by 306
Phosphatidylinositol 3-phosphates—at the interface between cell signalling and membrane traffic
Marat, A. L., & Haucke, V. (2016) · The EMBO Journal · doi:10.15252/embj.201593564 · Cited by 299
Horwitz, S. M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J. D., Morrow, S. N., et al. (2018) · Blood · doi:10.1182/blood-2017-08-802470 · Cited by 290 · cited 1×
“A phase I clinical trial showed the promising clinical activity of duvelisib, a PI3Kδ/γ inhibitor in T-cell lymphoma, by reprogramming macrophages (cells enriched in PI3Kγ) and inducing tumor cell-autonomous death [59,60].”
BackgroundPTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Costa, C., Wang, Y., Ly, A., Hosono, Y., Murchie, E., Walmsley, C. S., Huynh, T., Healy, C., Peterson, R., Yanase, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0830 · Cited by 270
Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30905-7 · Cited by 263 · cited 1×
“A phase I clinical trial showed an indication of a synergy between the PI3Kα-specific inhibitor alpelisib and the PARP inhibitor olaparib in epithelial ovarian cancer [24].”
BackgroundNoman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax7881 · Cited by 255 · cited 5×
“Indeed, Vps34 inhibition triggers PD-L1 expression [118] while PI3Kδ induces the expression of PD-1 in CD8+ cells [139].”
BackgroundInfluentialSchwartz, S., Wongvipat, J., Trigwell, C. B., Hancox, U., Carver, B. S., Rodrik-Outmezguine, V., Will, M., Yellen, P., de Stanchina, E., Baselga, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.008 · Cited by 246
The intricate regulation and complex functions of the Class III phosphoinositide 3-kinase Vps34
Backer, J. M. (2016) · Biochemical Journal · doi:10.1042/bcj20160170 · Cited by 238
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1006 · Cited by 231
Advances in the development of hybrid anticancer drugs
Fortin, S., & Bérubé, G. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.798296 · Cited by 223
Li, M., Li, M., Yang, Y., Liu, Y., Xie, H., Yu, Q., Tian, L., Tang, X., Ren, K., Li, J., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.011 · Cited by 221
Yoshioka, K., Yoshida, K., Cui, H., Wakayama, T., Takuwa, N., Okamoto, Y., Du, W., Qi, X., Asanuma, K., Sugihara, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2928 · Cited by 210
Li, M., Sala, V., De Santis, M. C., Cimino, J., Cappello, P., Pianca, N., Di Bona, A., Margaria, J. P., Martini, M., Lazzarini, E., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.030352 · Cited by 207
Burris, H. A., Flinn, I. W., Patel, M. R., Fenske, T. S., Deng, C., Brander, D. M., Gutierrez, M., Essell, J. H., Kuhn, J. G., Miskin, H. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30082-2 · Cited by 205
Costa, C., Ebi, H., Martini, M., Beausoleil, S. A., Faber, A. C., Jakubik, C. T., Huang, A., Wang, Y., Nishtala, M., Hall, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.007 · Cited by 203
Franco, I., Gulluni, F., Campa, C. C., Costa, C., Margaria, J. P., Ciraolo, E., Martini, M., Monteyne, D., De Luca, E., Germena, G., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.01.022 · Cited by 197
Pasquier, B. (2015) · Autophagy · doi:10.1080/15548627.2015.1033601 · Cited by 192
Willinger, T., & Flavell, R. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205305109 · Cited by 183
Braccini, L., Ciraolo, E., Campa, C. C., Perino, A., Longo, D. L., Tibolla, G., Pregnolato, M., Cao, Y., Tassone, B., Damilano, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8400 · Cited by 177
The Role of Phosphoinositide 3-Kinase C2α in Insulin Signaling
Falasca, M., Hughes, W. E., Dominguez, V., Sala, G., Fostira, F., Fang, M. Q., Cazzolli, R., Shepherd, P. R., James, D. E., & Maffucci, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704357200 · Cited by 167
Activity of any class IA PI3K isoform can sustain cell proliferation and survival
Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A., & Vanhaesebroeck, B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906461107 · Cited by 166
Class III PI-3-kinase activates phospholipase D in an amino acid–sensing mTORC1 pathway
Yoon, M.-S., Du, G., Backer, J. M., Frohman, M. A., & Chen, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201107033 · Cited by 161
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Fowler, N. H., Samaniego, F., Jurczak, W., Ghosh, N., Derenzini, E., Reeves, J. A., Knopińska-Posłuszny, W., Cheah, C. Y., Phillips, T., Lech-Maranda, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03433 · Cited by 161
mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate
Marat, A. L., Wallroth, A., Lo, W.-T., Müller, R., Norata, G. D., Falasca, M., Schultz, C., & Haucke, V. (2017) · Science · doi:10.1126/science.aaf8310 · Cited by 159
Targeting PI3K Signaling in Combination Cancer Therapy
Tostivint, E. P., Thibault, B., & Guillermet‐Guibert, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.002 · Cited by 156
Self-citationRegulation and cellular functions of class II phosphoinositide 3-kinases
Falasca, M., & Maffucci, T. (2012) · Biochemical Journal · doi:10.1042/bj20120008 · Cited by 151
Class II PI3K Functions in Cell Biology and Disease
Gulluni, F., De Santis, M. C., Margaria, J. P., Martini, M., & Hirsch, E. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.001 · Cited by 146
Mateo, J., Ganji, G., Lemech, C., Burris, H. A., Han, S.-W., Swales, K., Decordova, S., DeYoung, M. P., Smith, D. A., Kalyana-Sundaram, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0725 · Cited by 145
Bridges, D., Ma, J.-T., Park, S., Inoki, K., Weisman, L. S., & Saltiel, A. R. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-12-1034 · Cited by 141
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Song, K. W., Edgar, K. A., Hanan, E. J., Hafner, M. A., Oeh, J., Merchant, M. A., Sampath, D., Nannini, M. A., Hong, R., Phu, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0072 · Cited by 134
Pearson, H. B., Li, J., Meniel, V. S., Fennell, C. M., Waring, P., Montgomery, K. G., Rebello, R. J., Macpherson, A. A., Koushyar, S., Furic, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0867 · Cited by 132
Gulluni, F., Martini, M., Santis, M. C. D., Campa, C. C., Ghigo, A., Margaria, J. P., Ciraolo, E., Franco, I., Ala, U., Annaratone, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.002 · Cited by 118
Leibiger, B., Moede, T., Uhles, S., Barker, C. J., Creveaux, M., Domin, J., Berggren, P., & Leibiger, I. B. (2010) · The FASEB Journal · doi:10.1096/fj.09-148072 · Cited by 115
Deng, C., Lipstein, M. R., Scotto, L., Serrano, X. O. J., Mangone, M. A., Li, S., Vendôme, J., Hao, Y., Xu, X., Deng, S., et al. (2016) · Blood · doi:10.1182/blood-2016-08-731240 · Cited by 115
Hybrid Compounds as Multitarget Directed Anticancer Agents
Küçüksayan, E., & Özben, T. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160927155515 · Cited by 108
Dyczynski, M., Yu, Y., Otrocka, M., Parpal, S., Braga, T., Henley, A. B., Zazzi, H., Lerner, M., Wennerberg, K., Viklund, J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.028 · Cited by 108
Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer
Edling, C. E., Selvaggi, F., Buus, R., Maffucci, T., Di Sebastiano, P., Friess, H., Innocenti, P., Kocher, H. M., & Falasca, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1210 · Cited by 102
The Mammalian Class 3 PI3K (PIK3C3) Is Required for Early Embryogenesis and Cell Proliferation
Zhou, X., Takatoh, J., & Wang, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016358 · Cited by 101
Sun, P., Zhang, X., Wang, R.-J., Ma, Q., Xu, L., Wang, Y., Liao, H., Wang, H.-L., Hu, L., Kong, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003093 · Cited by 100
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
Eschweiler, S., Ramírez-Suástegui, C., Li, Y., King, E., Chudley, L., Thomas, J., Wood, O., von Witzleben, A., Jeffrey, D., McCann, K., et al. (2022) · Nature · doi:10.1038/s41586-022-04685-2 · Cited by 99
PTEN Functions by Recruitment to Cytoplasmic Vesicles
Naguib, A., Bencze, G., Cho, H., Zheng, W., Tocilj, A., Elkayam, E., Faehnle, C. R., Jaber, N., Pratt, C. P., Chen, M., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.03.011 · Cited by 97
Bago, R., Sommer, E., Castel, P., Crafter, C., Bailey, F. P., Shpiro, N., Baselga, J., Cross, D., Eyers, P. A., & Alessi, D. R. (2016) · The EMBO Journal · doi:10.15252/embj.201693929 · Cited by 90
Bilanges, B., Alliouachene, S., Pearce, W., Morelli, D., Szabadkai, G., Chung, Y.-L., Chicanne, G., Valet, C., Hill, J. M., Voshol, P. J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01969-4 · Cited by 82
Cracking the context-specific PI3K signaling code
Madsen, R. R., & Vanhaesebroeck, B. (2020) · Science Signaling · doi:10.1126/scisignal.aay2940 · Cited by 82
Boukhalfa, A., Nascimbeni, A. C., Ramel, D., Dupont, N., Hirsch, E., Gayral, S., Laffargue, M., Codogno, P., & Morel, E. (2020) · Nature Communications · doi:10.1038/s41467-019-14086-1 · Cited by 81
Autophagy Paradox of Cancer: Role, Regulation, and Duality
Verma, A. K., Bharti, P. S., Rafat, S., Bhatt, D., Goyal, Y., Pandey, K. K., Ranjan, S. K., Almatroodi, S. A., Alsahli, M. A., Rahmani, A. H., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8832541 · Cited by 81
Katso, R. M., Pardo, O. E., Palamidessi, A., Franz, C. M., Marinov, M., De Laurentiis, A., Downward, J., Scita, G., Ridley, A. J., Waterfield, M. D., et al. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-11-1083 · Cited by 81
VPS34 stimulation of p62 phosphorylation for cancer progression
Jiang, X., Bao, Y., Liu, H., Kou, X., Zhang, Z., Sun, F., Qian, Z., Lin, Z., Li, X., Liu, X., et al. (2017) · Oncogene · doi:10.1038/onc.2017.295 · Cited by 79
PI(3,4)P2-mediated cytokinetic abscission prevents early senescence and cataract formation
Gulluni, F., Prever, L., Li, H., Krafcikova, P., Corrado, I., Lo, W.-T., Margaria, J. P., Chen, A., De Santis, M. C., Cnudde, S. J., et al. (2021) · Science · doi:10.1126/science.abk0410 · Cited by 76
Isoyama, S., Mori, S., Sugiyama, D., Kojima, Y., Tada, Y., Shitara, K., Hinohara, K., Dan, S., & Nishikawa, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002279 · Cited by 76
Inactivation of the Class II PI3K-C2β Potentiates Insulin Signaling and Sensitivity
Alliouachene, S., Bilanges, B., Chicanne, G., Anderson, K. E., Pearce, W., Ali, K., Valet, C., Posor, Y., Low, P. C., Chaussade, C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.052 · Cited by 76
PI3K functions as a hub in mechanotransduction
Di-Luoffo, M., Ben-Meriem, Z., Lefebvre, P., Delarue, M., & Guillermet-Guibert, J. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2021.05.005 · Cited by 74
Self-citationPI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways
Zhao, Y., Montminy, T., Azad, T., Lightbody, E., Hao, Y., SenGupta, S., Asselin, E., Nicol, C., & Yang, X. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0593 · Cited by 70
Berenjeno, I. M., Guillermet-Guibert, J., Pearce, W., Gray, A., Fleming, S., & Vanhaesebroeck, B. (2012) · Biochemical Journal · doi:10.1042/bj20111741 · Cited by 69
Self-citationDwyer, C. J., Arhontoulis, D. C., Rivera, G. O. R., Knochelmann, H. M., Smith, A. S., Wyatt, M. M., Rubinstein, M. P., Atkinson, C., Thaxton, J. E., Neskey, D. M., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.201948455 · Cited by 67
How is the acyl chain composition of phosphoinositides created and does it matter?
Barneda, D., Cosulich, S., Stephens, L., & Hawkins, P. (2019) · Biochemical Society Transactions · doi:10.1042/bst20190205 · Cited by 65
P53 Mutations Change Phosphatidylinositol Acyl Chain Composition
Naguib, A., Bencze, G., Engle, D. D., Chio, I. I. C., Herzka, T., Watrud, K., Bencze, S., Tuveson, D. A., Pappin, D. J., & Trotman, L. C. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.010 · Cited by 65
Tiosano, D., Baris, H. N., Chen, A., Hitzert, M. M., Schueler, M., Gulluni, F., Wiesener, A., Bergua, A., Mory, A., Copeland, B., et al. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008088 · Cited by 65
The Class II Phosphoinositide 3-Kinase C2β Is Not Essential for Epidermal Differentiation
Harada, K., Truong, A. B., Cai, T., & Khavari, P. A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.11122-11130.2005 · Cited by 64
Goulielmaki, E., Bermúdez-Brito, M., Andreou, M., Tzenaki, N., Tzardi, M. N., de Bree, E., Tsentelierou, E., Makrigiannakis, A., & Papakonstanti, E. A. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0717-4 · Cited by 63
Phosphoinositide Diversity, Distribution, and Effector Function: Stepping Out of the Box
Choy, C. H., Han, B., & Botelho, R. J. (2017) · BioEssays · doi:10.1002/bies.201700121 · Cited by 59
Sullivan, R. J., Hong, D. S., Tolcher, A. W., Patnaik, A., Shapiro, G., Chmielowski, B., Ribas, A., Brail, L. H., Roberts, J., Lee, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3013 · Cited by 58
Millis, S. Z., Jardim, D. L., Albacker, L., Ross, J. S., Miller, V. A., Ali, S. M., & Kurzrock, R. (2019) · Cancer · doi:10.1002/cncr.31921 · Cited by 56
Scheffold, A., Jebaraj, B. M. C., Tausch, E., Bloehdorn, J., Ghia, P., Yahiaoui, A., Dolnik, A., Blätte, T. J., Bullinger, L., Dheenadayalan, R. P., et al. (2019) · Blood · doi:10.1182/blood.2018881029 · Cited by 55
A dual role for the class III PI3K, Vps34, in platelet production and thrombus growth
Valet, C., Levade, M., Chicanne, G., Bilanges, B., Cabou, C., Viaud, J., Gratacap, M., Gaits‐Iacovoni, F., Vanhaesebroeck, B., Payrastre, B., et al. (2017) · Blood · doi:10.1182/blood-2017-04-781641 · Cited by 55
Guillermet‐Guibert, J., Smith, L. B., Halet, G., Whitehead, M. A., Pearce, W. P., Rebourcet, D., Leon, K. E., Crépieux, P., Nock, G. E., Strömstedt, M., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005304 · Cited by 54
Self-citationWang, L., Budolfson, K., & Wang, F. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2010.10.035 · Cited by 51
Li, X., Su, Y., Hege, K., Madlambayan, G., Edwards, H., Knight, T., Polin, L., Kushner, J., Dzinic, S. H., White, K., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.233445 · Cited by 51
PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma
Ko, E., Seo, H., Jung, E. S., Ju, S., Kim, B., Cho, H., Kim, Y. J., Park, Y. M., Kim, J., & Jung, G. (2018) · Hepatology · doi:10.1002/hep.30307 · Cited by 50
Wu, K., Yang, L., Chen, J., Zhao, H., Wang, J., Xu, S., & Huang, Z.-H. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.05.056 · Cited by 49
Peng, W., Williams, L. J., Xu, C., Melendez, B., McKenzie, J. A., Chen, Y., Jackson, H. L., Voo, K. S., Mbofung, R. M., Leahey, S. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1259 · Cited by 49
p53 attenuates AKT signaling by modulating membrane phospholipid composition
Rueda-Rincon, N., Bloch, K., Derua, R., Vyas, R., Harms, A., Hankemeier, T., Khan, N. A., Dehairs, J., Bagadi, M., Binda, M. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4067 · Cited by 46
Targeting PI3K/AKT pathway in triple-negative breast cancer
Delaloge, S., & Deforceville, L. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30514-4 · Cited by 46
Kim, K., Kim, J., Sung, J. H., Suh, K. J., Lee, J. Y., Kim, S. H., Lee, J., Kim, J. W., Kim, Y. J., Kim, J. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68998-w · Cited by 45
A four-gene signature predicts survival in clear-cell renal-cell carcinoma
Dai, J., Lu, Y., Wang, J., Yang, L., Han, Y., Wang, Y., Yan, D., Ruan, Q., & Wang, S. (2016) · Oncotarget · doi:10.18632/oncotarget.12631 · Cited by 45
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component
Thibault, B., Ramos‐Delgado, F., Pons‐Tostivint, E., Therville, N., Cintas, C., Arcucci, S., Cassant‐Sourdy, S., Reyes‐Castellanos, G., Tosolini, M., Villard, A. V., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013502 · Cited by 44
Self-citationJanji, B., Hasmim, M., Parpal, S., De Milito, A., Berchem, G., & Noman, M. Z. (2020) · Autophagy · doi:10.1080/15548627.2020.1815439 · Cited by 43
Alliouachene, S., Bilanges, B., Chaussade, C., Pearce, W., Foukas, L. C., Scudamore, C. L., Moniz, L. S., & Vanhaesebroeck, B. (2016) · Diabetologia · doi:10.1007/s00125-016-3963-y · Cited by 42
Upregulation of REG Iα accelerates tumor progression in pancreatic cancer with diabetes
Zhou, L., Zhang, R., Wang, L., Shen, S.-M., Okamoto, H., Sugawara, A., Li, X., Wang, X., Noguchi, N., Yoshikawa, T., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25188 · Cited by 42
Conditional Knockout of Pik3c3 Causes a Murine Muscular Dystrophy
Reifler, A. N., Li, X., Cuttitta, A. J., McDade, J. R., Sabha, N. S., Michele, D. E., & Dowling, J. J. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.02.012 · Cited by 42
Chikh, A., Ferro, R., Abbott, J. J., Piñeiro, R., Buus, R., Iezzi, M., Ricci, F., Bergamaschi, D., Ostano, P., Chiorino, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7761 · Cited by 42
Jhaveri, K. L., Chang, M. T., Juric, D., Saura, C., Gambardella, V., Melnyk, A., Patel, M. R., Ribrag, V., Ma, C. X., Aljumaily, R. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2657 · Cited by 41
Flinn, I. W., Patel, M. R., Oki, Y., Horwitz, S. M., Foss, F. M., Allen, K. R., Douglas, M., Stern, H. M., Sweeney, J., Kharidia, J., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25228 · Cited by 40
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer
Santis, M. C. D., Gozzelino, L., Margaria, J. P., Costamagna, A., Ratto, E., Gulluni, F., Gregorio, E. D., Mina, E., Lorito, N., Bacci, M., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325117 · Cited by 38
Mavrommati, I., Cisse, O., Falasca, M., & Maffucci, T. (2016) · Scientific Reports · doi:10.1038/srep23277 · Cited by 37
Bian, C., Liu, Z., Li, D., & Zhen, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.8587 · Cited by 37
Grieco, G., Janssens, V., Gaide Chevronnay, H. P., N’Kuli, F., Van Der Smissen, P., Wang, T., Shan, J., Vainio, S., Bilanges, B., Jouret, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32389-z · Cited by 36
Xu, P., Yang, J., Liu, J., Yang, X., Liao, J., Yuan, F., Liu, B., & Chen, Q. (2018) · Oncology Reports · doi:10.3892/or.2018.6845 · Cited by 36
Class III Phosphoinositide 3‐Kinase/VPS34 and Dynamin are Critical for Apical Endocytic Recycling
Carpentier, S., N’Kuli, F., Grieco, G. E., Smissen, P. V. D., Janssens, V., Emonard, H., Bilanges, B., Vanhaesebroeck, B., Chevronnay, H. P. G., Pierreux, C. E., et al. (2013) · Traffic · doi:10.1111/tra.12079 · Cited by 35
Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors
Lynch, J. T., Polanska, U. M., Delpuech, O., Hancox, U. J., Trinidad, A. G., Michopoulos, F., Lenaghan, C., McEwen, R. K., Bradford, J. R., Polanski, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0676 · Cited by 35
Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival
Daydé, D., Guérard, M., Perron, P., Hatat, A.-S., Barrial, C., Eymin, B., & Gazzéri, S. (2015) · Oncogene · doi:10.1038/onc.2015.480 · Cited by 35
Hosford, S. R., Dillon, L. M., Bouley, S. J., Rosati, R., Yang, W., Chen, V. S., Demidenko, E., Morra, R. P., & Miller, T. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2764 · Cited by 34
Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth
Chilamakuri, R., & Agarwal, S. (2022) · Cancers · doi:10.3390/cancers14041067 · Cited by 34
PDPK1 regulates autophagosome biogenesis by binding to PIK3C3
Hu, B., Zhang, Y., Deng, T., Gu, J., Liu, J., Yang, H. M., Xu, Y., Yan, Y., Yang, F., Zhang, H., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1817279 · Cited by 34
Ni, H., Chai, P., Yu, J., Xing, Y., Wang, S., Fan, J., Ge, S., Wang, Y., Jia, R., & Fan, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2524-y · Cited by 33
Chaudhry, S. R., Lopes, J. L., Levin, N. K., Kalpage, H. A., & Tainsky, M. A. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00442-y · Cited by 32
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors
Lynch, J. T., Polanska, U. M., Hancox, U., Delpuech, O., Maynard, J., Trigwell, C., Eberlein, C. A., Lenaghan, C., Polański, R., Avivar‐Valderas, A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0183 · Cited by 32
Local synthesis of the phosphatidylinositol-3,4-bisphosphate lipid drives focal adhesion turnover
Posor, Y., Kampyli, C., Bilanges, B., Ganguli, S., Koch, P. A., Wallroth, A., Morelli, D., Jenkins, M., Alliouachene, S., Deltcheva, E. M., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.06.011 · Cited by 31
Zecchin, D., Moore, C., Michailidis, F., Horswell, S. D., Rana, S., Howell, M. T., & Downward, J. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202011987 · Cited by 31
Marqués, M., Tranchant, R., Risa-Ebrí, B., Suárez-Solís, M. L., Fernández, L. C., Pau, E. C. D. S., del Pozo, N., de Villarreal, J. M., Meiller, C., Allory, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1633 · Cited by 29
Dufour, M., Dormond-Meuwly, A., Pythoud, C., Demartines, N., & Dormond, O. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.014 · Cited by 26
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
Owusu‐Brackett, N., Zhao, M., Akçakanat, A., Evans, K. W., Yuca, E., Dumbrava, E. I., Jankú, F., & Meric‐Bernstam, F. (2020) · Oncotarget · doi:10.18632/oncotarget.27503 · Cited by 26
Liu, X., Wang, A., Liang, X., Liu, J., Zou, F., Chen, C., Zhao, Z., Deng, Y., Wu, H., Qi, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10650 · Cited by 24
Li, A., Chen, H., Lin, M., Zhang, C., Tang, E., Peng, J., Wei, Q., Li, H., & Yin, L. (2015) · PubMed · Cited by 24
Liu, T., Caihua, Z., Wang, S., Song, H., Wang, Z., Xu, X., Liu, H., Wang, Y., & Shen, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.9716 · Cited by 23
Cisse, O., Quraishi, M., Gulluni, F., Guffanti, F., Mavrommati, I., Suthanthirakumaran, M., Oh, L. C. R., Schlatter, J. N., Sarvananthan, A., Broggini, M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1472-9 · Cited by 22
Bashash, D., Safaroghli‐Azar, A., Dadashi, M., Safa, M., Momeny, M., & Ghaffari, S. H. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.02.007 · Cited by 21
Critical Role for Phosphatidylinositol-3 Kinase Vps34/PIK3C3 in ON-Bipolar Cells
He, F., Nichols, R. M., Kailasam, L., Wensel, T. G., & Agosto, M. A. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-26586 · Cited by 21
Arcucci, S., Ramos‐Delgado, F., Cayron, C., Therville, N., Gratacap, M., Basset, C., Thibault, B., & Guillermet‐Guibert, J. (2021) · Biochemical Journal · doi:10.1042/bcj20210004 · Cited by 21
Self-citationPI3KC2β inactivation stabilizes VE-cadherin junctions and preserves vascular integrity
Anquetil, T., Solinhac, R., Jaffre, A., Chicanne, G., Viaud, J., Darcourt, J., Orset, C., Geuß, E., Kleinschnitz, C., Vanhaesebroeck, B., et al. (2021) · EMBO Reports · doi:10.15252/embr.202051299 · Cited by 20
Karlsson, T., Krakstad, C., Tangen, I. L., Høivik, E. A., Pollock, P. M., Salvesen, H. B., & Lewis, A. E. (2016) · Oncotarget · doi:10.18632/oncotarget.13989 · Cited by 18
Ultimo, S., Simioni, C., Martelli, A. M., Zauli, G., Evangelisti, C., Celeghini, C., McCubrey, J. A., Marisi, G., Ulivi, P., Capitani, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15542 · Cited by 17
Heitz, S. D., Hamelin, D. J., Hoffmann, R. M., Greenberg, N., Salloum, G., Erami, Z., Khalil, B. D., Shymanets, A., Steidle, E. A., Gong, G. Q., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006032 · Cited by 17
Anderson, K., Ryan, N. M., Alkhimovitch, A., Siddiqui, A., & Oghumu, S. (2021) · Cancers · doi:10.3390/cancers13050953 · Cited by 17
Class II but Not Second Class—Prospects for the Development of Class II PI3K Inhibitors
Mountford, S. J., Zheng, Z., Sundaram, K., Jennings, I. G., Hamilton, J. R., & Thompson, P. E. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500354e · Cited by 15
Loss of Class III Phosphoinositide 3-Kinase Vps34 Results in Cone Degeneration
Rajala, A., He, F., Anderson, R. E., Wensel, T. G., & Rajala, R. V. S. (2020) · Biology · doi:10.3390/biology9110384 · Cited by 15
An iron-dependent metabolic vulnerability underlies VPS34-dependence in RKO cancer cells
Kobylarz, M. J., Goodwin, J. M., Kang, Z. B., Annand, J. W., Hevi, S., O’Mahony, E., McAllister, G., Reece-Hoyes, J. S., Wang, Q., Alford, J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235551 · Cited by 14
Cintas, C., Douché, T., Dantes, Z., Mouton‐Barbosa, E., Bousquet, M., Cayron, C., Therville, N., Pont, F., Ramos‐Delgado, F., Guyon, C., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0981 · Cited by 14
Self-citationZhao, H., Wu, C.-P., Zhou, X., Diao, P., Xu, Y., Liu, J., Wang, J., Huang, X., Liu, W.-L., Chen, Z., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01728-4 · Cited by 14
E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing
Millán‐Uclés, Á., Zuluaga, S., Marqués, M., Vallejo-Díaz, J., Sanz, L., Cariaga-Martínez, A. E., Real, F. X., & Carrera, A. C. (2016) · Oncotarget · doi:10.18632/oncotarget.13414 · Cited by 13
Rational Design of Multitargeted Tyrosine Kinase Inhibitors: A Novel Approach
Barchéchath, S., Williams, C., Saade, K., Lauwagie, S., & Jean‐Claude, B. J. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00786.x · Cited by 12
Piazzi, M., Bavelloni, A., Cenni, V., Salucci, S., Stella, A. B., Tomassini, E., Scotlandi, K., Blalock, W. L., & Faenza, I. (2022) · Molecules · doi:10.3390/molecules27092742 · Cited by 11
Bono, J. S. D., Hansen, A. R., Choudhury, A. D., Cook, N., Heath, E. I., Higano, C. S., Linch, M. D., Martín-Liberal, J., Rathkopf, D. E., Wisinski, K. B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy284.042 · Cited by 9
Sethi, I., Cai, Z., Roberts, T. M., & Yuan, G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0588 · Cited by 8
Mamidi, M. K., Mahmud, H., Maiti, G. P., Mendez, M. T., Fernandes, S. M., Vesely, S. K., Chakrabarty, J. H., Brown, J. R., & Ghosh, A. K. (2022) · Leukemia · doi:10.1038/s41375-022-01595-0 · Cited by 5
Diehl, A., Hannan, L. M., & Chiorean, E. G. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.424 · Cited by 5
Rao, S., Thibault, B., Peyrard, L., Larroque‐Lombard, A., Rupp, M., Thauvin, C., & Jean‐Claude, B. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179569 · Cited by 3
Self-citationIs targeting autophagy a promising lead to unveil the cloak of invisibility in pancreatic cancer?
Cayron, C., Rigal, S., & Guillermet‐Guibert, J. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101622 · Cited by 1
Self-citation
Cited by
Li, H., Wen, X., Ren, Y., Fan, Z., Zhang, J., He, G., & Fu, L. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02072-1 · Cited by 125
Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy
Han, B., Lin, X., & Hu, H. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-29 · Cited by 53
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers
Shan, K. S., Bonano-Rios, A. M., Theik, N. W. Y., Hussein, A. M., & Blaya, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041973 · Cited by 35
Isoform-selective targeting of PI3K: time to consider new opportunities?
Cirillo, D., Diceglie, M., & Nazaré, M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.002 · Cited by 24
Breast Cancer: Molecular Pathogenesis and Targeted Therapy
Samad, M. A., Ahmad, I., Khan, M. R., Suhail, M., Zughaibi, T. A., Al-Abbasi, F. A., Alhosaini, K. A., Khan, M. S., Kumer, A., & Tabrez, S. S. M. (2025) · MedComm · doi:10.1002/mco2.70404 · Cited by 34
Metadata
- Authors
- Thibault, B., Ramos-Delgado, F., & Guillermet-Guibert, J.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm, CNRS, 31037 Toulouse, France
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-01-27
- Volume
- 15
- Issue
- 3
- Pages
- 784
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9913247
- OpenAlex
- W4318485540
- Cited by
- 40
- References
- 151
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 12 · 2023: 2
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- Funders
- ANR JCJC program Radiance (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- MSCA-ITN/ETN PhD-PI3K (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- IUCT-O/ICR translational program (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- Ligue Régionale Contre Le Cancer (2020, 2021) (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- Fondation Arc (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- ANR (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- Laboratoire d’Excellence (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- phosphatidylinositol 3-kinase, PI3K inhibitors, isoform-selective inhibitors, cancer therapy, tumor microenvironment, tumor cell proliferation, cancer metabolism, combination therapy, PI3K signaling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.